Etiology and Treatment of Alcohol Dependence

康涅狄格大学酒精研究中心（UCONN RC）的这份P50申请要求五个 多年来，该中心的研究计划对酒精依赖的脆弱性和有前途的资金 生物和心理社会治疗干预。行政核心描述了康州大学ARC的 组织框架、与研究和出版物有关的质量控制机制， 研究设施。访问学者计划，咨询和指导活动，以及期刊编辑 活动加强了康州大学ARC作为区域和国家资源的作用。研究项目#1将重点 几种可能的饮酒科普（DTC），压力相关的途径（包括遗传），可能会增加 前大学生酗酒及酒精相关问题的易感性 再加上毕业后的几年。本研究将检查日水平3个评估波的变化 DTC动机与其前因和结果之间的关联，以及这些日常变化是否 过程与人格因素和其他变量的个体差异有关。继续我们 中心的重点是新的治疗方法，我们提出了两个额外的研究。双重强化权变 酒精使用障碍的管理（CM），研究项目#2，将评估强化的效果。 在患者中，磷脂酰乙醇（PEth）结果与CM一起用于治疗几种结局 在社区治疗中心。据推测，这种组合将导致更大的出勤率，更多 PEth阴性样本，自我报告的非饮酒天数比例较高，重度饮酒比例较低。 喝酒的日子研究#3是一项安慰剂对照试验，旨在评价度他雄胺的安全性和有效性 男性和女性中，减少饮酒和治疗效果的持续性将是 考察如果复制，FKBP 5变异体对度他雄胺治疗效果的调节作用将扩大 越来越多的潜在遗传预测因子，促进了个性化药物的开发 治疗建议AUD。最后，拟议的试点研究核心将支持多达六项研究， 直接关系到该中心的脆弱性和酒精依赖的新疗法和帮助的主题 支持初级研究人员和酒精研究新手。

This P50 application from the University of Connecticut Alcohol Research Center (UCONN RC) requests five years of funding for the Center's research programs on vulnerability to alcohol dependence and promising biological and psychosocial treatment interventions. The Administrative Core describes the UConn ARC's organizational framework, quality control mechanisms related to research and publications, and supporting research facilities. The visiting scholars program, consulting and mentoring activities, and journal editorship activities strengthen the UConn ARC's role as a regional and national resource. Research Project #1 will focus on several possible drinking to cope (DTC), stress-related pathways (including genetic) that may increase the susceptibility for developing heavy drinking and alcohol-related problems among former college students six plus years after graduation. This study will examine changes across 3 assessment waves in day-level associations among DTC motivation and its antecedents and outcomes and whether changes in these daily processes are related to individual differences across personality factors and other variables. Continuing our Center's emphasis on novel treatments, we propose two additional studies. Dual reinforcement contingency management (CM) for alcohol use disorders, Research Project #2, will evaluate the effects of reinforcing negative phosphatidylethanol (PEth) results alongside CM for attendance on several outcomes among patients in community treatment centers. It is hypothesized that this combination will result in greater attendance, more PEth negative samples, higher proportions of self-reported non-drinking days, and lower proportions of heavy drinking days. Research study #3 is a placebo controlled trial to evaluate the safety and efficacy of dutasteride among male and females with AUD. Reductions in drinking and the persistence of treatment effects will be examined. If replicated, the moderation of dutasteride treatment effects by a variant in FKBP5 would expand the growing list of potential genetic predictors, facilitating the development of personalized medication treatment recommendations for AUD. Finally, the proposed pilot studies core will support up to six studies that relate directly to the Center's themes of vulnerability and novel treatments for alcohol dependence and help support junior investigators and faculty new to alcohol research.